Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ayahuasca/Chronic Pain

Ayahuasca for Chronic Pain

9 papers and 0 clinical trials exploring ayahuasca as a treatment for chronic pain.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
IndicationOver 1.5 billion worldwide.

Chronic Pain

Chronic pain is increasingly recognised as a multifaceted condition that may respond to psychedelic therapies, which are gaining attention in clinical settings for their potential efficacy in pain management. Recent research indicates that compounds such as psilocybin and MDMA are entering clinical trials aimed at exploring their therapeutic effects on chronic pain syndromes.

Full Chronic Pain profile

Academic Research

9 papers
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
August 15, 2025
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.
Paywallindividual

Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A

This fMRI study explores the effects of psilocybin (a serotonergic psychedelic) and Salvinorin-A (a kappa-opioid receptor agonist) on resting-state functional connectivity (FC) in nonhuman primates. It reveals both drugs influence FC around the thalamus, claustrum, prefrontal cortex (PFC), and default mode network (DMN), with similarities and differences noted between them.

Published
June 25, 2024
Journal
ACS Chemical Neuroscience
Authors
Bagdasarian, F. A., Hansen, H. D., Chen, J., Yoo, C. H., Placzek, M. S., Hooker, J. M., Wey, H. Y.
Paywallmeta

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

This meta-analysis (s=6) explored the therapeutic effects of psilocybin, LSD and ayahuasca on depressive symptoms in the clinical setting. When administered with psychological support, all psychedelics led to significant reductions in depressive symptoms at all measured timepoints (1-day, 1-week, 3-5 weeks, and 6-8 weeks). Some limitations include the small sample sizes used in most individual studies and the use of a cross-over design for long-term follow-up, which made it difficult to include those results in the meta-analysis.

Published
October 7, 2022
Journal
Journal of Affective Disorders
Authors
Kopra, E., Cleare, A. J., Rucker, J., Ko, K.
Open Accessmeta

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

This mixed-methods systematic review of 44 clinical studies (598 patients) found serotonergic psychedelics and MDMA to be generally well tolerated but noted that adverse events were poorly defined and likely underreported. Common acute AEs were nausea, headache and anxiety, late AEs included fatigue and low mood, one serious MDMA-related cardiac event occurred, and qualitative data suggest challenging psychological experiences can also have therapeutic value, underlining the need for systematic, detailed AE assessment in future trials.

Published
August 26, 2022
Journal
Journal of Psychopharmacology
Authors
Breeksema, J. J., Kuin, B. W., Kamphuis, J., Van Den Brink, W., Vermetten, E., Schoevers, R. A.
Open Accessindividual

On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli Occupation

This qualitative case study (n=3) investigates the sociopharmacology of ayahuasca within the context of ritual ceremonies between Palestinians and Israelis and found that it occasioned revelatory events that confronted the participants with the oppressive nature of their surrounding political structure. These revelatory experiences led the participant to develop a universalist counterhegemonic worldview, which motivated them to restructure the ritual space of ayahuasca use to be more inclusive of Palestinians and their culture.

Published
August 27, 2021
Journal
Frontiers in Psychology
Authors
Roseman, L., Karkabi, N.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Chronic Pain yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Chronic Pain trials Full Ayahuasca profile Full Chronic Pain profile